(Q38384492)

2 September 2017

title

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer (English)

1 reference

2 September 2017

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

James Chih-Hsin Yang

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Shirish M Gadgeel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Alice T Shaw

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Ramaswamy Govindan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Leena Gandhi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Mark A Socinski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

D Ross Camidge

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Luigi De Petris

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Dong-Wan Kim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Alberto Chiappori

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Michael Duruisseaux

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Lucio Crino

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Tommaso De Pas

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Eric Dansin

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Antje Tessmer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Ji-Youn Han

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Walter Bordogna

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sophie Golding

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Ali Zeaiter

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sai-Hong Ignatius Ou

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

English

0 references

publication date

31 October 2016

1 reference

Journal of Clinical Oncology

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

4079-4085

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27863201%20AND%20SRC:MED&resulttype=core&format=json

Irradiation of brain metastases from lung cancer: a retrospective study

5 June 2020

cites work

1 reference

12 December 2020

Drug delivery to the central nervous system: a review

1 reference

12 December 2020

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

1 reference

12 December 2020

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

12 December 2020

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

1 reference

12 December 2020

Characteristics of long-term survivors of brain metastases from lung cancer

1 reference

12 December 2020

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

1 reference

12 December 2020

Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

1 reference

12 December 2020

Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy

1 reference

12 December 2020

Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies

1 reference

12 December 2020

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

1 reference

12 December 2020

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

1 reference

12 December 2020

Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer

1 reference

12 December 2020

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

1 reference

12 December 2020

Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib

1 reference

12 December 2020

Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis

1 reference

12 December 2020

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

1 reference

12 December 2020

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

1 reference

12 December 2020

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

1 reference

12 December 2020

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

1 reference

12 December 2020

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

1 reference

12 December 2020